See 1999.
Methods | Allocation: randomised (no further description). Blindness: double (no further description). Duration: 5 weeks (preceeded by 3 weeks prestudy stablisation with trifluoperazine 20‐30 mg/day. This was reduced to 5‐10mg/day during week 1 and discontinued during week 2). Consent: given. Setting: hospital. | |
Participants | Diagnosis: schizophrenia (DSM‐IV). N=20. Age: >18 years. Sex: 14M, 6F. History: chronic, partial responders to neuroleptics, residual sypmptoms. Exclusions: not stated. | |
Interventions | 1. Risperidone: 4‐6 mg/day. N=10.
2. Haloperidol: 15‐30 mg/day. N=10. Benztropine mesylate as required. |
|
Outcomes | Mental state: PANSS. Adverse effects: SAS. Leaving the study early.* | |
Notes | * Not stated, assumed to be zero. | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Allocation concealment? | Unclear risk | B ‐ Unclear |